In PTEN-deficient cancers, AKT activation-induced GSK3β suppression results in the disruption of CHD1 proteolysis and aberrant accumulation of the CHD1 protein (25–27), which contributes to tumor development and tumor microenvironment (TME) remodeling. Here, PTEN is linked to cancer.